AFAnwar Fathollahi

Anwar Fathollahi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anwar Fathollahi has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Farshid Yeganeh

    Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    3 shared publications
  • Saeed Aslani

    Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    3 shared publications
  • Mahdi Mahmoudi

    Rheumatology Research center, Tehran University of medical sciences, Tehran, Iran

    2 shared publications
  • Meisam Barati

    Department of Cellular and Molecular Nutrition, National Nutrition and Food Technology Research Institute, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Mostafa Haji Molla Hoseini

    Medical Nanotechnology and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Nima Rezaei

    Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center Tehran University of Medical Sciences Tehran Iran

    2 shared publications

Latest Publications

  • Open Access

    Engineered Probiotics for the Management of Congenital Metabolic Diseases: A Systematic Review

    by Meisam Barati, Erfan Mosharkesh, Amir Hossein Tahmassian, Maryam Khodaei, Masoumeh Jabbari, Ali Kalhori, Mohsen Alipour, Afshin Abdi Ghavidel, Sajad Khalili-Moghadam, Anwar Fathollahi, et al.

    Meisam Barati, Erfan Mosharkesh, Amir Hossein Tahmassian, Maryam Khodaei, Masoumeh Jabbari, Ali Kalhori, Mohsen Alipour, Afshin Abdi Ghavidel, Sajad Khalili-Moghadam, Anwar Fathollahi, and Sayed Hossein Davoodi. Prev Nutr Food Sci 2024;29:1-7. https://doi.org/10.3746/pnf.2024.29.1.1


  • The immunomodulatory potential of murine adipose-derived mesenchymal stem cells is enhanced following culture on chitosan film

    by Sheida Farrokhi, Fattah Sotoodehnejadnematalahi, Anwar Fathollahi, Mostafa Haji Molla Hoseini, Seyed Mahmoud Hashemi, Farshid Yeganeh


  • Can Oral Tolerance Explain the Inconsistencies Associated with Total Dietary Diversity and Colon Cancer? A Mechanistic Systematic Review

    by Masoumeh Jabbari, Meisam Barati, Anwar Fathollahi, Fardin Javanmardi, Fatemeh Hemmati, Fariba Farahmand, Parvin Mirmiran, Hassan Eini-Zinab, Amin Mousavi Khaneghah

    Among the gastrointestinal tract cancers, the risk of colon cancer is strongly dependent on dietary factors. For the first time in the current review, all the original case-control studies, associated with the correlation between total dietary diversity score and colon cancer risk, were evaluated. In this regard, three databases, including PubMed/MEDLINE, Scopus, and Web of Sciences, were investigated to retrieve the related citations from 1990 until 2019. Among the included citations, three studies were finally included. In these included studies, the dietary diversity score was evaluated with 129-item and 800-item FFQs. Findings reveal that total dietary diversity can increase the risk of colon cancer in men, but not women; while, one study using 57-item FFQ reported the beneficial association of total dietary diversity with colon cancer among men. Significant demand for conducting more research to investigate the real mechanistic effects of dietary diversity on the risk of colon cancer development was demonstrated due to the inconsistent, questionable, and incomplete findings associated with the included studies.


  • Open Access

    EL4-derived Exosomes Carry Functional TNF-related Apoptosis-inducing Ligand that are Able to Induce Apoptosis and Necrosis in the Target Cells

    by Sajjad Tavakkoli, Fattah Sotoodehnejadnematalahi, Anwar Fathollahi, Mojgan Bandehpour, Mostafa Haji Molla Hoseini, Farshid Yeganeh

    Exosomes released by tumor cells play critical roles in tumor progression, immune cell suppression, and cancer metastasis. The aim of the present study was to investigate whether the exosomes released by EL4 cells carry a functional TNF-related apoptosis-inducing ligand (TRAIL) molecule. Exosomes were harvested from the supernatants of EL4 cell culture, and the shape, size, and identity of EL4-derived exosomes were evaluated by utilizing scanning electron microscopy, dynamic light scattering, and dot-blot method. The expression of mRNA and TRAIL protein in EL4 cells and EL4-exosomes were investigated using real-time PCR method and dot-blot analysis. Moreover, the effects of EL4-derived exosomes on cell death in a TRAIL-sensitive cell line (4T1) were studied by using flow cytometry (annexin V/propidium iodide (PI) staining) and fluorescent microscopy analyses (acridine orange/ethidium bromide staining). The results showed that EL4 cells continuously and without the need for stimulation, produce exosomes that carry TRAIL protein. In addition, EL4-derived exosomes were capable to induce apoptosis as well as necrosis in 4T1 cells. It was ultimately revealed that EL4 cells express TRAIL protein and release exosomes containing functional TRAIL. Moreover, the released exosomes were able to induce apoptosis and necrosis in a TRAIL-sensitive cell line. Further studies are needed to reveal the potential roles of tumor-derived exosomes in the pathogenesis of cancers.


  • Epigenetics in osteoarthritis: Novel spotlight

    by Anwar Fathollahi, Saeed Aslani, Ahmadreza Jamshidi, Mahdi Mahmoudi

    Osteoarthritis (OA) is the most common type of arthritis and no longer is considered as an absolute consequence of joint mechanical use (wear and tear); rather recent data demonstrate the pivotal role of inflammatory mediators in the development and progression of this disease. This multifactorial disease results from several environmental and inherited factors. Genetic cannot solely explain all the contribution share of inheritance and, this way, it is speculated that epigenetics can play a role, too. Moreover, environmental factors can induce local epigenetic changes. The epigenetic contribution to OA pathogenesis occurs at all of its levels, DNA methylation, histone modification, microRNA, and long noncoding RNA. In fact, during early phases of OA pathogenesis, environmental factors employ epigenetic mechanisms to provide a positive feedback for the OA‐related pathogenic mechanisms and pathways with an ultimate outcome of a well‐established clinical OA. These epigenetic changes stay during clinical disease and prevent the body natural healing and regenerative processes to work properly, resulting in an incurable disease condition. In this review article, we aimed to have an overview on the studies performed with regard to understanding the role of epigenetics in the etiopathogenesis of OA and highlighted the importance of such kind of regulatory mechanisms within this context.


  • The role of killer-cell immunoglobulin-like receptor (KIR) genes in susceptibility to inflammatory bowel disease: systematic review and meta-analysis

    by Anwar Fathollahi, Saeed Aslani, Shayan Mostafaei, Nima Rezaei, Mahdi Mahmoudi

    Inflammatory bowel disease (IBD) is a chronic inflammatory disease, which involves the gut and comprises of Crohn’s disease (CD) and ulcerative colitis (UC). Immune cells, including natural killer (NK) cells, play an important role in the pathogenesis of the disease. Killer immunoglobulin-like receptors (KIRs) are NK cell surface receptors, which ligate to the class I major histocompatibility complex (MHC) and have inhibitory or activating effects on the NK cells. The aim of this study was to perform a meta-analysis of the six studies evaluating the association in the polymorphisms of these KIR genes and the IBD risk (4 UC and 5 CD studies).


  • Mesenchymal stem cell transplantation in systemic lupus erythematous, a mesenchymal stem cell disorder

    by A Fathollahi, N B Gabalou, S Aslani

    Systemic lupus erythematosus (SLE) is a chronic autoimmune and inflammatory disorder with involvement of several organs and systems such as the kidney, lung, brain and the hematopoietic system. As the most prevailing organ manifestation, lupus nephritis is the major cause of mortality and morbidity in SLE patients. The most classically and widely administered immunosuppressive medications, namely corticosteroids and cyclophosphamide, have eventuated in a remarkable amelioration in disease complications over the last few years and reduced the progression to end-stage multiorgan failure. Mesenchymal stem cells (MSCs) are considered as non-hematopoietic and multipotential progenitor cells, which are able to differentiate into multiple cell lineages such as chondrocytes, osteoblasts, myoblasts, endothelial cells, adipocytes, neuron-like cells, hepatocytes and cardiomyocytes. MSCs from SLE patients have demonstrated defects such as aberrant cytokine production. Moreover, impaired phenotype, growth and immunomodulatory functions of MSCs from patients with SLE in comparison to healthy controls have been reported. Therefore, it is hypothesized that SLE is potentially an MSC-mediated disease and, as a result, allogeneic rather than autologous MSC transplantation can be argued to be a potentially advantageous therapy for patients with SLE. On the other hand, the MSC senescence phenomenon may meet the current therapeutic approaches with challenges and demand more attention. Here, we discuss MSC transplantations to date in animal models and humans and focus on the MSC senescence complications in SLE patients.


  • sICAM-1, sVCAM-1 and sE-Selectin Levels in Type 1 Diabetes

    by Anwar Fathollahi, Ahmad Massoud, Ali Akbar Amirzargar, Babak Aghili, Ensieh Nasli Esfahani, Nima Rezaei

    Background/Objective: This study was performed to compare soluble levels of adhesion molecules between diabetic patients and controls and to assess their possible association with long-term complications of type 1 diabetes (T1D). Methods: Forty-eight patients with T1D and 39 healthy controls were enrolled in this study. The plasma level of adhesion molecules was measured by sandwich enzyme-linked immunosorbent assay technique. Results: Higher sVCAM 1 (soluble vascular cell adhesion molecule 1) levels correlated with older age of onset of T1D. The plasma level of sICAM 1 (soluble intercellular adhesion molecule 1) was significantly increased, while sE selectin was significantly decreased in patients with T1D, compared to controls. There was no significant relationship between these plasma-level variations and the long-term complications of T1D. Conclusion: Although plasma levels of cell adhesion molecules are different in T1D patients and healthy controls, they might not be good candidate markers for prognosis of disease.